You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Do Statin Use Recommendations Change Significantly in European Guidelines?

  • Authors: News Author: Sue Hughes; CME Author: Laurie Barclay, MD
  • CME / ABIM MOC / CE Released: 8/19/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 8/19/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for cardiologists, pharmacists, physician assistants, internists, nurses, nurse practitioners, diabetologists and endocrinologists, family medicine and primary care clinicians, and other members of the health care team who treat and manage patients in whom statin therapy may be indicated.

The goal of this activity is for learners to be better able to compare clinical performance of the 2021 European-European Society of Cardiology, American College of Cardiology/American Heart Association, UK National Institute for Health and Care Excellence, and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines for atherosclerotic cardiovascular disease primary prevention with statins.

Upon completion of this activity, participants will:

  • Compare the clinical performance of the 2021 European Society of Cardiology, American College of Cardiology/American Heart Association, UK National Institute for Health and Care Excellence, and EAS guidelines for atherosclerotic cardiovascular disease primary prevention with statins, based on a population-based contemporary cohort from the Copenhagen General Population Study
  • Evaluate the clinical implications of comparative clinical performance of the 2021 European Society of Cardiology, American College of Cardiology/American Heart Association, UK National Institute for Health and Care Excellence, and European Atherosclerosis Society guidelines for atherosclerotic cardiovascular disease primary prevention with statins, based on a population-based contemporary cohort from the Copenhagen General Population Study
  • Outline implications for the healthcare team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Sue Hughes

    Journalist
    Medscape Medical News

    Disclosures

    Sue Hughes has no relevant financial relationships.

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Laurie Barclay, MD, has the following relevant financial relationships:
    Formerly owned stocks in: AbbVie

Editor/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-22-268-H01-P).

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 8/19/2023. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Do Statin Use Recommendations Change Significantly in European Guidelines?

Authors: News Author: Sue Hughes; CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 8/19/2022

Valid for credit through: 8/19/2023, 11:59 PM EST

processing....

References

  1. Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG. Statin eligibility for primary prevention of cardiovascular disease according to 2021 European prevention guidelines compared with other international guidelines. JAMA Cardiol. Published online July 6, 2022. https://jamanetwork.com/journals/jamacardiology/fullarticle/2793729. Accessed July 7, 2022.
  2. Navar AM, Fonarow GC, Pencina MJ. Time to revisit using 10-year risk to guide statin therapy. JAMA Cardiol. Published online July 6, 2022. https://jamanetwork.com/journals/jamacardiology/article-abstract/2793732. Accessed July 7, 2022.
« Return to: Do Statin Use Recommendations Change Significantly in European Guidelines?
  • Print